Abstract 1714P
Background
Ensuring equal opportunity to participate in clinical trials is important. We analyzed the effectiveness of efforts to ensure geographically equal access to cancer clinical trials in Korea.
Methods
Clinical trials registered between 2012 and 2023 in Korea were captured from the Ministry of Food and Drug Safety database. To measure geographic disparity, we calculated the ratio of clinical trials conducted in local areas compared to those conducted in metropolitan areas and called it the trial geographical disparity index (TGDI). Regression analysis was used to analyze the annual trend of the TGDI.
Results
From 191 hospitals, 9424 cancer clinical trials were identified. The mean TGDI was 46%, indicating that cancer patients living in local areas can only access 46% of cancer clinical trials available to patients living in metropolitan areas. The disparities did not increase or decrease over 12 years. The situation varies among cancer sites, however. There was an improvement in the geographical disparity in lung cancer (p = 0.019), whereas a deterioration existed in pancreatic and prostate cancer (p = 0.035 and 0.016, respectively). Additionally, TGDI has worsened in clinical trials for domestically developed drugs (R-squared 0.58). In contrast, it has significantly improved for trials initiated by global pharmaceutical companies (R-squared 0.61), especially in lung and breast cancer (p = 0.016 and 0.005).
Conclusions
Although geographical disparities in access to cancer clinical trials seem to have been fixed in Korea, our data suggest that sponsor-initiated phase II/III trials conducted by global pharmaceutical companies may have a significant role in lowering the geographical barrier and ensuring equal access.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Cancer Center, Republic of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23